Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination…

By M. Genovese, J. McKay, E. Nasonov, E. Mysler, N. A. da Silva, E. Alecock, T. Woodworth, J. Gómez-Reino. Arthritis & Rheumatism, 2008

877 citations recorded by the source corpus.